OneSource Specialty Pharma and Formycon AG announce strategic manufacturing partnership for biosimilars

image credit- freepik

Bengaluru-based OneSource Specialty Pharma, a multi-modality specialty pharma CDMO, and Formycon AG, an independent biosimilar developer headquartered in Munich, have announced a strategic manufacturing partnership for biosimilars.

Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics’ facility in Bangalore.

The collaboration brings together Formycon´s Biosimilar development excellence with OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.

The partnership reflects the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model — that OneSource is specifically positioned to deliver.

Formycon brings a strong track record in biosimilar development and commercialisation, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.